The trial obtained equally its Major endpoints, with semaglutide two.4 mg demonstrating statistically sizeable and exceptional enhancements in liver fibrosis with no worsening of steatohepatitis, in addition to resolution of steatohepatitis without any worsening of liver fibrosis in individuals with